Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor

Nature

Volumn 491, Issue 7425, 2012, Pages 613-617

  Kim, Beomkyu ^a   Eggel, Alexander ^b   Tarchevskaya, Svetlana S ^a   Vogel, Monique ^b   Prinz, Heino ^c   Jardetzky, Theodore S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

E2 79; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E FC EPSILON RECEPTOR IALPHA COMPLEX; OMALIZUMAB; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALLERGY; ANTIBODY; ASTHMA; CELL ORGANELLE; INHIBITION; INHIBITOR; LIGAND; MOLECULAR ANALYSIS; MUTATION; PROTEIN; REACTION KINETICS;

ALLERGY; ALLOSTERISM; ARTICLE; BINDING SITE; CONFORMATION; DRUG RECEPTOR BINDING; INHIBITION KINETICS; PRIORITY JOURNAL; WILD TYPE;

ALLOSTERIC REGULATION; ANKYRIN REPEAT; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FLUORESCENCE; IMMUNOGLOBULIN E; KINETICS; LIGANDS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGE; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

EID: 84869880199     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11546     Document Type: Article

References (34)

1. Kraft, S. & Kinet, J. P. New developments in FceRI regulation, function and inhibition. Nature Rev. Immunol. 7, 365-378 (2007).
2. Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nature Rev. Immunol. 8, 205-217 (2008).
3. D'Amato, G., Bucchioni, E., Oldani, V. & Canonica, W. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (Omalizumab). Treat. Respir. Med. 5, 393-398 (2006).
4. Chang, T. W. The pharmacological basis of anti-IgE therapy. Nature Biotechnol. 18, 157-162 (2000).
5. Holdom, M. D. et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FceRI. Nature Struct. Mol. Biol. 18, 571-576 (2011).
6. Dhaliwal, B. et al. Crystal structureofIgE boundtoits B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FceRI. Proc. Natl Acad. Sci. USA 109, 12686-12691 (2012).
7. 3-4 revealed in multiple crystal forms. J. Mol. Biol. 393, 176-190 (2009).
8. Wurzburg, B. A., Garman, S. C. & Jardetzky, T. S. StructureofthehumanIgE-FcCe3-Ce4 reveals conformational flexibility in the antibody effector domains. Immunity 13, 375-385 (2000).
9. Eggel, A., Baumann, M. J., Amstutz, P., Stadler, B. M. & Vogel, M. DARPins as bispecific receptor antagonists analyzed for immunoglobulinE receptor blockage. J. Mol. Biol. 393, 598-607 (2009).
10. Baumann, M. J., Eggel, A., Amstutz, P., Stadler, B. M. & Vogel, M. DARPins against a functional IgE epitope. Immunol. Lett. 133, 78-84 (2010).
11. Eggel, A. et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66, 961-968 (2011).
12. Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P. & Jardetzky, T. S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FceRIa. Nature 406, 259-266 (2000).
13. Basu, M. et al. Purification and characterization of human recombinant IgE-Fc fragments that bind to the human high affinity IgE receptor. J. Biol. Chem. 268, 13118-13127 (1993).
14. Wang, B. et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via FceRI. J. Exp. Med. 175, 1353-1365 (1992).
15. Mirkina, I., Schweighoffer, T. & Kricek, F. Inhibition of human cord blood-derived mast cell responses by anti-FceRI mAb 15/1 versus anti-IgE Omalizumab. Immunol. Lett. 109, 120-128 (2007).
16. Mendonsa, S. D. & Bowser, M. T. In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal. Chem. 76, 5387-5392 (2004).
17. Wiegand, T. W. et al. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fce receptor I. J. Immunol. 157, 221-230 (1996).
18. Zheng, L. et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem. Biophys. Res. Commun. 375, 619-622 (2008).
19. Wright, J. D. & Lim, C. Prediction of an anti-IgE binding site on IgE. Protein Eng. 11, 421-427 (1998).
20. 3-4 in a closed, non-receptor binding conformation. J. Biol. Chem. http://dx.doi.org/10.1074/jbc.M112.407502jbcM112.407502 (2012).
21. 21 channels is simply explained by competition for individual attachment points. J. Biol. Chem. 268, 18580-18585 (1993).
22. Gutfreund, H. Kinetics for the Life Sciences. Receptors, Transmitters and Catalysts (Cambridge Univ. Press, 1995).
23. Hoops, S. et al. COPASI\a COmplex PAthway SImulator. Bioinformatics 22, 3067-3074 (2006).
24. He, M. M. et al. Small-molecule inhibition of TNF-a. Science 310, 1022-1025 (2005).
25. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
26. Wang, C. C. et al. Negative and positive site-site interactions, and their modulation by pH, insulin analogs, and monoclonal antibodies, are preserved in the purified insulin receptor. Proc. Natl Acad. Sci. USA 85, 8400-8404 (1988).
27. Lowenthal, J. W. et al. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 135, 3988-3994 (1985).
28. Boulain, J. C. & Menez, A. Neurotoxin-specific immunoglobulins accelerate dissociation of the neurotoxin-acetylcholine receptor complex. Science 217, 732-733 (1982).
29. Garman, S. C., Kinet, J. P. & Jardetzky, T. S. Crystal structure of the human high-affinity IgE receptor. Cell 95, 951-961 (1998).
30. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. inMethods Enzymol. Vol. 276 (eds Carter, J. C. W. & Sweet, R. M.) 307-326 (Academic, 1997).
31. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
32. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126-2132 (2004).
33. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).
34. Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477-486 (1996).